Physician profile
Deepika Arvind Panday
NPI 1659829182
$2,134.85
in general payments reported to CMS, 2019-2025
33 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $187 · 2021: $25.24 · 2022: $133 · 2023: $663 · 2024: $333 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $306.07 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Beta Bionics, INC. | $174.00 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Gilead Sciences, INC. | $137.36 | 2020-2023 | |
| Pfizer INC. | $135.14 | 2019-2025 | |
| Lilly USA, LLC | $131.16 | 2022-2025 | Jardiance, Mounjaro, Lyumjev |
| Sequel Med Tech, LLC | $123.54 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.13 | 2019-2025 | Jardiance |
| Medtronic, INC. | $115.13 | 2022-2025 | Minimed 780g |
| Radius Health, INC. | $111.45 | 2023-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $104.41 | 2019-2020 | |
| Abbvie INC. | $90.78 | 2023-2025 | |
| Insulet Corporation | $66.47 | 2022-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $52.30 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $51.45 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $42.38 | 2023 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.98 | 2023-2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $30.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $28.84 | 2023 | |
| Madrigal Pharmaceuticals | $26.40 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $24.19 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $23.18 | 2019 | |
| Ascensia Diabetes Care US INC. | $20.93 | 2023 | |
| Biogen, INC. | $20.74 | 2019 | |
| Mannkind Corporation | $19.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.34 | 2019 | |
| Shire North American Group INC | $18.18 | 2019 | |
| Cequr Corporation | $17.08 | 2024 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $16.95 | 2025 | Unithroid |
| Recordati_rare_diseases_inc. | $16.43 | 2025 | Isturisa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.37 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $14.51 | 2023 | Baqsimi |
| Takeda Pharmaceuticals U.S.A., INC. | $12.96 | 2020 | |
| Amgen INC. | $12.81 | 2023 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Panday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.